Yulareb FC Tablets
PDF Leaflet Revision Date: 28 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Adjuvant treatment of HR-positive, HER2-negative early breast cancer and advanced/metastatic breast cancer.
Dosage (summary)
150 mg twice daily with endocrine therapy; 200 mg twice daily as monotherapy.
Onset of Action / Duration
Onset: 6-8 days, Duration: Continuous as long as clinical benefit.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; use effective contraception.
Key Drug Interactions
- Avoid ketoconazole
- Monitor with strong CYP3A inhibitors
- Avoid CYP3A inducers
Contraindications
- Hypersensitivity to abemaciclib
- Pregnancy
- Breastfeeding
Common side effects
- Diarrhoea
- Neutropenia
- Fatigue
- Nausea
- Vomiting
Counselling Points
- Start antidiarrheal therapy at first sign of loose stools.
- Monitor for signs of infection and report fever.
- Avoid grapefruit products.
- Take doses at the same times daily and swallow whole.
Serious warnings
- Severe diarrhoea
- Neutropenia
- Interstitial lung disease
- Hepatotoxicity
Important Disclaimer
The Yulareb FC Tablets professional information leaflet below is the property of Eli Lilly (SA) and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
